hyaluronidase

(redirected from Vitrase)
Also found in: Dictionary, Medical, Encyclopedia.
  • noun

Synonyms for hyaluronidase

an enzyme (trade name Hyazyme) that splits hyaluronic acid and so lowers its viscosity and increases the permeability of connective tissue and the absorption of fluids

Related Words

References in periodicals archive ?
The Vitrase 6,200-unit single-dose vial was discontinued, although Vitrase is still available in 200-U/mL vials.
Although the delay is not terribly helpful it has been done for the very best reasons - to ensure that Vitrase has the best possible chance of being successful, " he said.
Three of the groups will each receive one of three different doses of Vitrase (7.
5%, VITRASE (hyaluronidase injection) Ovine, 200 USP Units/mL, BEPREVE (bepotastine besilate ophthalmic solution) 1.
1) million (d) Unrealized loss on the mark-to-market adjustment to derivative instruments (e) Income from revised Vitrase collaboration agreement with ISTA pharmaceuticals (f) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): Tax effect Non-GAAP pre-tax adjustments of $7.
The recent increase in our sales force has not only resulted in a successful launch of BEPREVE, but has helped drive first half revenue growth and higher market shares for our three core eye care products Xibrom(TM), Istalol and Vitrase," stated Vicente Anido, Jr.
3 million (d) Interest income related to previously paid state income taxes and reversal of interest expense related to tax settlements (e) Unrealized gain on the mark-to-market adjustment to derivative instruments (f) Termination of ISTA Vitrase collaboration agreement (including interest income of $0.
0 (e) Patent infringement settlement (f) Income tax benefit for previously paid state income taxes and tax effect for non-GAAP adjustments (g) ISTA Vitrase collaboration fee ALLERGAN, INC.
On June 7th, ISTA announced FDA approval of Istalol for glaucoma, which is the company's second FDA approval; the company announced FDA approval for Vitrase as a spreading agent in May.
Vitrase has received "fast-track" designation from the FDA for the treatment of vitreous hemorrhage.
On July 5, 2001 ISTA announced it had completed enrollment in both of its Phase III clinical trials for Vitrase, an investigational drug being developed by the company for the treatment of severe vitreous hemorrhage.
On July 5, 2001, ISTA announced it had completed enrollment in both of its Phase III clinical trials for Vitrase, an investigational drug being developed by the company for the treatment of severe vitreous hemorrhage.